EXEL exelixis.com Net earnings per share growth forecast for next year

Corporate company logo of Exelixis Inc. (EXEL)

Exelixis, Inc. (EXEL) generates a steady cash flow and high margins due to the strong demand for Cabometyx. The GURU.Markets platform features this chart, where the projected growth in the company's net profit currently stands at 14.60. Production capacities are functioning flawlessly, ensuring the manufacture of medications. However, long-term success depends on clinical trial outcomes, patent protection, and insurance reimbursement policies.

EXEL: Exelixis Inc Net earnings per one share growth forecast for next year 07/04/2022 - 11/14/2026

Financial and market metric breakdowns for exelixis.com (EXEL)

- share price and consensus valuation forecast:
Stock Price Exelixis Corp|EXEL - Analyst Consensus Forecast
- market capitalization data:
Market Value Exelixis|EXEL - Value Adjusted for Debt and Cash
- company book value details:
Book Value per Share Exelixis|EXEL - Book Value of Business|Market Capitalization to Book Value Ratio exelixis.com|EXEL - Company Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Exelixis, Inc.|EXEL - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Exelixis|EXEL - Company Cumulative Debt|Debts to Book Capitalization Exelixis|EXEL - Company Long-Term Indebtedness|Company Current Liabilities Exelixis|Quick Liquidity Indicator exelixis.com
- earnings and valuation multiples information:
EXEL - Profit After Payment of Taxes|Projected Future Earnings Exelixis, Inc.|EXEL - Company Value to Net Income|Forward P/E Multiple Exelixis, Inc.|EXEL - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Exelixis|EXEL - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Exelixis|EXEL - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months exelixis.com|EXEL - Earnings per share trend in current year|Expected earnings per share growth for next year Exelixis, Inc.
- sales and revenue data:
EXEL - Company Total Revenue|Projected Sales Volume Exelixis Corp|EXEL - Price to Sales|Forward Price-to-Revenue Multiple Exelixis
Fundamental company analysis:Exelixis Corp, EXEL
Brand item of exelixis.com

The earnings growth forecast for the coming year reflects the expected earnings per share (EPS) dynamics, serving as an indicator of the issuer's future financial stability and market value. For Exelixis, Inc. (EXEL), this metric depends directly on the outcome of costly clinical trials and the protection of its patent monopoly. By analyzing this 12-month expected EPS growth chart, one can assess the market's level of optimism regarding new drugs. Sharp fluctuations in this metric signal high risks of a drawdown during a change in the regulatory cycle.

Competing companies

GMAB (Genmab US) - Earnings growth forecast for next year|Earnings growth forecast for next year Nuvalent Therapeutics|Net earnings per share growth forecast for next year Kymera Therapeutics (KYMR)|IDYA (ideayabio.com) - Expected earnings per share trend next year|Earnings growth forecast for next year ELVN (Enliven Therapeutics, Inc.)|Net earnings per one share growth forecast for next year ORIC Pharmaceuticals Inc|Relay Pharma - Earnings growth forecast for next year|Expected net earnings per share growth next year Nurix Corp|TYRA (Tyra Biosciences, Inc.) - Expected earnings per share growth for next year|VSTM: Projected earnings per share increase next year|GLUE (Monte Rosa Therapeutics, Inc.) - Earnings growth forecast for next year|Expected net earnings per share growth next year Cullinan Oncology CGEM|Earnings growth forecast for next year IMRX|C4 Therapeutics Corp - Projected earnings per share growth rate for next year|Black Diamond - Expected earnings per share growth for next year|Expected earnings per share trend next year RPTX|PMVP: Expected earnings per share growth for next year|Karyopharm Therapeutics - Projected earnings per share increase next year|PPCB: Earnings growth forecast for next year|Cyclacel - Expected earnings per share trend next year|AADI (Aadi Bioscience Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year Aileron ALRN|Net earnings per share growth forecast for next year Blueprint Medicines (BPMC)|GLYC (glycomimetics.com) - Expected earnings per share trend next year|Earnings growth forecast for next year SWTX (SpringWorks)